Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro

Rose Fife, B. Stott, R. E. Carr

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The cyclooxygenase (COX) family of enzymes has been implicated in cell proliferation and angiogenesis in many tumors, including colon cancer. Indeed, cyclooxygenase-2 (COX-2) inhibitors recently have been approved for use for prophylaxis in individuals with familial adenomatous polyposis. We now report on the effects of a selective COX-2 inhibitor, celecoxib, on cell proliferation, matrix metalloproteinase (MMP) concentration, angiogenesis using an in vitro assay, and apoptosis in several human cancer cell lines. We demonstrate that celecoxib modestly reduces proliferation in some cell lines and does not affect MMP concentrations. However, celecoxib significantly decreases microtubule formation in stimulated human umbilical vein endothelial cells (HUVECs) exposed to cancer cell supernatants, an in vitro angiogenesis model, when compared to controls incubated with supernatants from untreated cells. Celecoxib does not consistently induce apoptosis in these cell lines, as determined by DNA laddering in agarose gels and by a caspase assay. Thus, it appears that COX-2 inhibitors have beneficial effects in reducing malignant cell behavior in vitro and warrant further study to elucidate their mechanisms of action and to examine their mechanisms of action in this role and their utility in vivo in a variety of animal and human tumors.

Original languageEnglish
Pages (from-to)228-232
Number of pages5
JournalCancer Biology and Therapy
Volume3
Issue number2
StatePublished - Feb 2004

Fingerprint

Celecoxib
Cyclooxygenase 2 Inhibitors
Matrix Metalloproteinases
Cell Line
Neoplasms
Cell Proliferation
Apoptosis
Adenomatous Polyposis Coli
Human Umbilical Vein Endothelial Cells
Prostaglandin-Endoperoxide Synthases
Caspases
Microtubules
Sepharose
Colonic Neoplasms
Gels
In Vitro Techniques
DNA
Enzymes

Keywords

  • Angiogenesis
  • Apoptosis
  • Cancer cells
  • Cyclooxygenase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro. / Fife, Rose; Stott, B.; Carr, R. E.

In: Cancer Biology and Therapy, Vol. 3, No. 2, 02.2004, p. 228-232.

Research output: Contribution to journalArticle

@article{3a1351d1c1ca4f0cb6c1d6aaf0c9c639,
title = "Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro",
abstract = "The cyclooxygenase (COX) family of enzymes has been implicated in cell proliferation and angiogenesis in many tumors, including colon cancer. Indeed, cyclooxygenase-2 (COX-2) inhibitors recently have been approved for use for prophylaxis in individuals with familial adenomatous polyposis. We now report on the effects of a selective COX-2 inhibitor, celecoxib, on cell proliferation, matrix metalloproteinase (MMP) concentration, angiogenesis using an in vitro assay, and apoptosis in several human cancer cell lines. We demonstrate that celecoxib modestly reduces proliferation in some cell lines and does not affect MMP concentrations. However, celecoxib significantly decreases microtubule formation in stimulated human umbilical vein endothelial cells (HUVECs) exposed to cancer cell supernatants, an in vitro angiogenesis model, when compared to controls incubated with supernatants from untreated cells. Celecoxib does not consistently induce apoptosis in these cell lines, as determined by DNA laddering in agarose gels and by a caspase assay. Thus, it appears that COX-2 inhibitors have beneficial effects in reducing malignant cell behavior in vitro and warrant further study to elucidate their mechanisms of action and to examine their mechanisms of action in this role and their utility in vivo in a variety of animal and human tumors.",
keywords = "Angiogenesis, Apoptosis, Cancer cells, Cyclooxygenase inhibitors",
author = "Rose Fife and B. Stott and Carr, {R. E.}",
year = "2004",
month = "2",
language = "English",
volume = "3",
pages = "228--232",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro

AU - Fife, Rose

AU - Stott, B.

AU - Carr, R. E.

PY - 2004/2

Y1 - 2004/2

N2 - The cyclooxygenase (COX) family of enzymes has been implicated in cell proliferation and angiogenesis in many tumors, including colon cancer. Indeed, cyclooxygenase-2 (COX-2) inhibitors recently have been approved for use for prophylaxis in individuals with familial adenomatous polyposis. We now report on the effects of a selective COX-2 inhibitor, celecoxib, on cell proliferation, matrix metalloproteinase (MMP) concentration, angiogenesis using an in vitro assay, and apoptosis in several human cancer cell lines. We demonstrate that celecoxib modestly reduces proliferation in some cell lines and does not affect MMP concentrations. However, celecoxib significantly decreases microtubule formation in stimulated human umbilical vein endothelial cells (HUVECs) exposed to cancer cell supernatants, an in vitro angiogenesis model, when compared to controls incubated with supernatants from untreated cells. Celecoxib does not consistently induce apoptosis in these cell lines, as determined by DNA laddering in agarose gels and by a caspase assay. Thus, it appears that COX-2 inhibitors have beneficial effects in reducing malignant cell behavior in vitro and warrant further study to elucidate their mechanisms of action and to examine their mechanisms of action in this role and their utility in vivo in a variety of animal and human tumors.

AB - The cyclooxygenase (COX) family of enzymes has been implicated in cell proliferation and angiogenesis in many tumors, including colon cancer. Indeed, cyclooxygenase-2 (COX-2) inhibitors recently have been approved for use for prophylaxis in individuals with familial adenomatous polyposis. We now report on the effects of a selective COX-2 inhibitor, celecoxib, on cell proliferation, matrix metalloproteinase (MMP) concentration, angiogenesis using an in vitro assay, and apoptosis in several human cancer cell lines. We demonstrate that celecoxib modestly reduces proliferation in some cell lines and does not affect MMP concentrations. However, celecoxib significantly decreases microtubule formation in stimulated human umbilical vein endothelial cells (HUVECs) exposed to cancer cell supernatants, an in vitro angiogenesis model, when compared to controls incubated with supernatants from untreated cells. Celecoxib does not consistently induce apoptosis in these cell lines, as determined by DNA laddering in agarose gels and by a caspase assay. Thus, it appears that COX-2 inhibitors have beneficial effects in reducing malignant cell behavior in vitro and warrant further study to elucidate their mechanisms of action and to examine their mechanisms of action in this role and their utility in vivo in a variety of animal and human tumors.

KW - Angiogenesis

KW - Apoptosis

KW - Cancer cells

KW - Cyclooxygenase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=7644228315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7644228315&partnerID=8YFLogxK

M3 - Article

C2 - 14726667

AN - SCOPUS:7644228315

VL - 3

SP - 228

EP - 232

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 2

ER -